10-Q: Ensysce Biosciences Reports Q2 2024 Results, Cites Ongoing Development and Funding Needs
Quarterly Report
Ensysce Biosciences reported its financial results for the second quarter of 2024, highlighting ongoing research and development activities and the need for additional funding.
Summary
- Ensysce Biosciences, a clinical-stage biotech company, released its unaudited financial results for the quarter ended June 30, 2024.
- The company is focused on developing safer prescription drugs using its proprietary technology platforms, with a primary focus on abuse and overdose-resistant pain technology.
- Ensysce's lead product candidate, PF614, is an extended-release TAAP prodrug of oxycodone, and the company is also developing MPAR technology for overdose protection.
- The company reported a net loss of $1.97 million for the quarter and $5.08 million for the six months ended June 30, 2024.
- Federal grant funding was $0.18 million for the quarter and $0.49 million for the six months ended June 30, 2024, a decrease compared to the same periods in 2023.
- Research and development expenses were $0.95 million for the quarter and $1.73 million for the six months ended June 30, 2024, a decrease compared to the same periods in 2023.
- General and administrative expenses were $1.19 million for the quarter and $2.56 million for the six months ended June 30, 2024.
- The company's cash and cash equivalents were $1.04 million as of June 30, 2024.
- Ensysce has incurred significant operating losses since inception and expects to continue to incur net losses for the foreseeable future.
- The company's ability to continue as a going concern is dependent on its ability to obtain adequate financing and achieve profitable operations.
Sentiment
Score: 4
Explanation: The document highlights significant financial losses and the need for additional funding, which are negative indicators. However, the company is actively pursuing innovative solutions and has made progress in its development programs, which provides some positive sentiment. The overall sentiment is cautiously negative due to the financial challenges.
Positives
- The company successfully completed a warrant inducement in February 2024, generating approximately $4.7 million in gross proceeds.
- Research and development expenses decreased compared to the same periods in 2023, indicating potential cost management.
- The company is actively pursuing the development of innovative solutions for pain relief with reduced risk of opioid misuse and overdose.
Negatives
- The company reported a significant net loss of $1.97 million for the quarter and $5.08 million for the six months ended June 30, 2024.
- Federal grant funding decreased compared to the same periods in 2023.
- The company's cash and cash equivalents are low at $1.04 million as of June 30, 2024.
- The company has incurred significant operating losses since inception and expects to continue to incur net losses for the foreseeable future.
- The company's ability to continue as a going concern is dependent on its ability to obtain adequate financing.
Risks
- The company's ability to continue as a going concern is dependent on its ability to obtain adequate financing.
- The company has not generated any product revenue and may never be able to develop or commercialize a marketable product.
- The company's product candidates may not be successful in limiting or impeding abuse, overdose, or misuse.
- The company's clinical trials may fail to replicate positive results from earlier studies.
- The company may be unable to successfully market or gain market acceptance of its product candidates.
- The company may be unable to obtain and maintain sufficient intellectual property protection.
- The company's common stock may be delisted from Nasdaq.
- The company is subject to risks related to third-party dependencies for laboratory, clinical development, and manufacturing services.
Future Outlook
The company expects to continue to incur net losses for the foreseeable future and will need to raise additional capital to fund its operations. The timing and amount of future funding requirements will depend on the progress of research and development efforts and related general and administrative support. The company anticipates funding operations through public or private equity or debt financings or other sources, such as potential collaboration agreements.
Management Comments
- Management believes in the viability of its strategy to ultimately realize revenues and in its ability to raise additional funds.
- Management cannot be certain that additional funding will be available on acceptable terms, or at all.
- Management has concluded that the company's financial statements are fairly stated in all material respects in accordance with GAAP for each of the periods presented.
Industry Context
Ensysce operates in the biotechnology and pharmaceutical industry, focusing on developing innovative solutions for pain management with reduced risk of opioid misuse and overdose. This is a significant area of unmet need, and the company's technology platforms are aimed at addressing these challenges. The company faces competition from other pharmaceutical companies developing similar technologies and therapies.
Comparison to Industry Standards
- The company's financial results are typical for a clinical-stage biotech company that has not yet generated product revenue.
- The company's research and development expenses are in line with other companies in the industry that are developing novel therapies.
- The company's cash position is relatively low compared to other companies in the industry, which highlights the need for additional funding.
- The company's reliance on federal grants for funding is common in the biotech industry, but it also highlights the need for alternative funding sources.
- The company's focus on abuse-deterrent and overdose-resistant technologies is a growing trend in the pharmaceutical industry, driven by the opioid crisis.
Related Party Transactions
- As of June 30, 2024, the Company held a $0.2 million senior secured convertible promissory note plus accrued interest and 0.4 million warrants exercisable for common stock at $1.5675 per share issued from a board member in connection to the issuance of the 2023 Notes.
Stakeholder Impact
- Shareholders face the risk of dilution from future equity offerings.
- Employees face uncertainty due to the company's financial challenges.
- Customers (potential patients) may benefit from the company's innovative therapies if they are successfully developed and commercialized.
- Suppliers and creditors face the risk of non-payment if the company is unable to secure additional funding.
Next Steps
- The company will continue preclinical studies and clinical trials for its product candidates.
- The company will seek regulatory approval for its product candidates.
- The company will establish sales, marketing, and distribution capabilities for its product candidates.
- The company will continue to seek additional funding to support its operations.
Key Dates
| Date | Description |
|---|---|
| 2018-09 | The National Institutes of Health (NIH) through the National Institute on Drug Abuse (NIDA) awarded the Company a research and development grant related to the development of its MPAR overdose prevention technology. |
| 2019-09 | The NIH/NIDA awarded the Company a second research and development grant related to the development of its TAAP/MPAR abuse deterrent technology for Opioid Use Disorder. |
| 2020-12 | The Company executed the GEM Agreement, under which an investor agreed to provide the Company with a share subscription facility of up to $60.0 million. |
| 2021-07-02 | The Company's shares were publicly listed. |
| 2021-09-24 | First closing of the sale of senior secured convertible promissory notes. |
| 2021-11-05 | Second closing of the sale of senior secured convertible promissory notes. |
| 2022-06-30 | First closing of the sale of senior secured convertible promissory notes. |
| 2022-08-08 | Second closing of the sale of senior secured convertible promissory notes. |
| 2022-12-09 | The Company's December 2022 registered direct offering of common stock closed. |
| 2023-02-06 | The Company's February 2023 registered direct offering of common stock and private placement warrants closed. |
| 2023-05-12 | The Company's May 2023 registered direct offering of common stock closed. |
| 2023-10-23 | The Company entered into a Securities Purchase Agreement (SPA) for an aggregate financing of $1.8 million. |
| 2023-10-25 | First closing under the SPA, the Company issued senior secured convertible promissory notes and warrants. |
| 2023-11-29 | Second closing under the SPA, the Company issued additional notes and warrants. |
| 2024-02-12 | The Company executed an Inducement Letter with certain holders of existing warrants. |
| 2024-02-14 | The closing of the 2024 warrant inducement offering occurred. |
| 2024-04-25 | The Company and a board member entered into a forbearance agreement. |
| 2024-06-30 | End of the reporting period for the quarterly results. |
| 2024-08-12 | Date of share count for the report. |
| 2024-08-14 | Date of the report. |
Keywords
biotechnology, pharmaceuticals, clinical stage, opioid, pain management, abuse deterrent, overdose protection, TAAP, MPAR, PF614, financial results, research and development, funding, warrants
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.